Relapses in multibacillary leprosy patients after Multidrug therapy

Leprosy Review

Volumn 79, Issue 3, 2008, Pages 320-324

  Poojabylaiah, Mitranna ^a   Marne, Ramesh Bhat ^a   Varikkodan, Rajina ^a   Bala, Nandakishore ^a   Dandakeri, Sukumar ^a   Martis, Jacintha ^a  

^a FATHER MULLER MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; DAPSONE; RIFAMPICIN;

ADULT; AGED; ARTICLE; BORDERLINE LEPROSY; CASE REPORT; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LEPROMATOUS LEPROSY; MAJOR CLINICAL STUDY; MALE; MULTIBACILLARY LEPROSY; PATIENT ASSESSMENT; RECURRENCE RISK; RECURRENT DISEASE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEPROSTATIC AGENTS; LEPROSY; MALE; MIDDLE AGED; MYCOBACTERIUM LEPRAE; RECURRENCE; RISK FACTORS; WORLD HEALTH ORGANIZATION;

EID: 56449119841     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. WHO study group chemotherapy of leprosy, for control program, World Health Organisation Geneva 1982 Tech: Rep Ser 675.
2. Girdhar BK, Girdhar A, Kumar A. Relapse in multibacillary leprosy patients: Effect of length of therapy. Lepr Rev, 2000; 71: 144-153.
3. st century. Report of the international leprosy association, technical forum. Lepr Rev, 2002; 73: S13-S16.
4. WHO: A Guide to leprosy Control, second edition, 1988; pp. 40.
5. WHO: MDT Questions and answer. 1991; pp. 21.
6. World Health Organization, WHO Expert Committee on Leprosy, Seventh Report. WHO, Technical Report Series 874, World Health Organization Geneva, 1998.
7. Sharma VK. Leprosy: Classification and clinical features. In: Valia RG, Valia AR (eds). IADVL text book and atlas of dermatology Bhalani publishing house, Mumbai, 2001; pp. 1578-1603.
8. WHO Study Group: Chemotherapy of Leprosy for Control Programmes, Geneva. 1982; Tech Resp Ser 675.
9. World Health Organization, WHO Expert Committee on Leprosy. Sixth report. WHO Technical Report Series 768. World Health Organization, Geneva, 1988.
10. Leprosy division, Directorate General of Health Services, National Leprosy Eradication Programme in India, Guidelines for Multidrug Treatment in new endemic district, Ministry of Health and Family Welfare. Nirman Bhavan, New Delhi: India. 1994.
11. Rao PN. Recent advances in the control programme and therapy of leprosy. Indian dermatol venereol leprol, 2004; 70: 269-276.
12. World Health Organization. Risk of relapse in leprosy. The Leprosy Unit, Division of Tropical Diseases: World Health Organization, Geneva: 1994; 94.1.
13. Jamet P, Ji B, the Marchoux Chemotherapy Study Group. Relapse after long-term follow-up of multibacillary patients. Treated by WHO multibacillary regimen. Int J Lepr Other Mycobact Dis, 1995; 63: 195-201.
14. Chen Y, Li W, Jiang C, Ye G. Studies on risk of leprosy relapses in China: relapses after treatment with Multidrug therapy. Int J Lepr Other Mycobact Dis, 1999; 67: 379-387.
15. Marchoux Chemotherapy Study Group. Relapses in multibacillary leprosy patients after stopping treatment with rifampicin containing combined regimens. Int J Lep Other Mycobact Dis, 1992; 60: 525-535.
16. Gebre S, Saunderson P, Byoss P. Relapse after fixed duration multiple drug therapy; the AMFES Cohort. Lepr Rev, 2000; 71: 325-331.
17. Desikan KV. Relapse, Reactivation and Reinfection. Ind J Lepr, 1995; 67: 3-10.